Work

Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS)

Year: 2017

Type: article

Source: Leukemia Research

DOI: 10.1016/s0145-2126(17)30151-0

Authors: E.M. Stein, A.T. Fathi, C.D. DiNardo, D.A. Pollyea, R.T. Swords, G.J. Roboz, R. Collins, M.A. Sekeres, R.M. Stone, E.C. Attar, A. Tosolini, Q. Xu, M. Amatangelo, I. Gupta, R.D. Knight, S. de Botton, M.S. Tallman, H.M. Kantarjian

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

Open Access status: closed

OpenAlex ID: W2611488013

FWCI:

Cites:

Cited by:

Related to: 10